2025
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-cause mortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodIMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerBladder sparing therapyAll-cause mortalityOncological outcomesRadical cystectomyCancer-specific mortalityNon-invasive diseaseBCG-unresponsiveBladder cancerPathological outcomesT1 diseaseT1 patientsCIS patientsMedian timeProgression to muscle-invasive bladder cancerBCG-unresponsive NMIBC patientsImpact of pathological stageImpact of tumor stageInternational cohortMuscle-invasive bladder cancerAssociated with significant morbiditySingle-institution seriesHeterogeneous group of patientsCompare oncologic outcomesSummary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer *
Apolo A, Baumann B, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, Greenberg S, Delacroix S, Dignam J, Efstathiou J, Feldman A, Foster J, Hahn N, Hall E, Hansel D, Hoffman-Censits J, Kamat A, Kamran S, Khani F, Lerner S, Lipman R, Mann B, McConkey D, McKiernan J, Rose T, Smith A, Tangen C, Amiri A, Weinstock C, West P, Milowsky M, Black P. Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer *. Bladder Cancer 2025, 11: 23523735251319185. PMID: 40034245, PMCID: PMC11863732, DOI: 10.1177/23523735251319185.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerClinical Trials Planning MeetingNext generation of clinical trialsGeneration of clinical trialsInvasive bladder cancerClinical trialsNational Cancer InstituteBladder cancerHigh-risk non-muscle invasive bladder cancerNational Clinical Trials NetworkCancer InstituteMultidisciplinary expert consensusClinical trial conceptsClinical trial designClinical Trials NetworkCombination therapyTrial conceptsTrials NetworkExpert consensusTrial designTherapyPlanning meetingsCancerTrialsTask Force
2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBCG-unresponsive NMIBCBacillus Calmette-GuerinOncological outcomesBladder cancerIntravesical gemcitabineNon-muscle invasive bladder cancerBacillus Calmette-Guerin treatmentHazard ratioBacillus Calmette-Guerin therapyBacillus Calmette-Guerin groupCompare oncologic outcomesInvasive bladder cancerCox proportional hazard ratiosKaplan-Meier methodNoninvasive bladder cancerRates of PFSProportional hazard ratiosAssociated with lower ratesFood and Drug Administration guidelinesBCG-unresponsiveDrug Administration guidelinesGemcitabine-docetaxelBCG therapyProgression-freeONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomesNATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT
Taylor J, Annapureddy D, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Davaro F, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT. Urologic Oncology Seminars And Original Investigations 2024, 42: s49. DOI: 10.1016/j.urolonc.2024.01.152.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBCG-unresponsive NMIBCBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsiveRate of cystectomyCohort of patientsOncological outcomesRadical cystectomyBladder cancer deathAdequate BCGBCG therapyOncological riskCancer deathRetrospective multi-center cohortInternational cohort of patientsAdequate BCG therapyAlternative intravesical agentsIntravesical mitomycin CMaintenance BCG therapyNatural historyUpfront radical cystectomyInferior oncologic outcomesMulti-center cohort of patientsUpper tract diseaseEFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
Boorjian S, Narayan V, Master V, Konety B, Shore N, Kamat A, Dinney C, Bivalacqua T, Kates M, Montgomery J, Lerner S, Crispen P, Steinberg G, Agarwal P, Schuckman A, Svatek R, Lane B, Karsh L, Bjurlin M, Brown G, Lotan Y, Inman B, Williams M, Cookson M, Chang S, Kim E, Sankin A, O'Donnell M, Jakobsen J, Juul K. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL. Urologic Oncology Seminars And Original Investigations 2024, 42: s70. DOI: 10.1016/j.urolonc.2024.01.201.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerPhase 3 studyFollow-up resultsNadofaragene firadenovecCarcinoma in situPapillary diseaseTreatment optionsFollow-upProgression to muscle-invasive diseaseDiscontinuation due to adverse eventsOpen-label phase 3 studyVector-based gene therapyTreatment of adult patientsBenefit-to-risk ratioDuration of follow-upCystectomy-free survivalHigh-grade recurrenceMuscle-invasive diseaseDurability of responseDuration of CRInvasive bladder cancerMonths of treatmentNovel treatment optionsBCG-unresponsiveCorrelation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.
St-Laurent M, Plets M, Black P, Singh P, McConkey D, Lucia S, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Tangen C, Thompson I, Meeks J, Caruso V, Phillips K, Bicocca V, Levin T, Lerner S. Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605. Journal Of Clinical Oncology 2024, 42: 529-529. DOI: 10.1200/jco.2024.42.4_suppl.529.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerEvent-free survivalEvent-free survival probabilityComprehensive genomic profilingLow-risk patientsGenomic profilingBCG-unresponsiveRisk scoreBladder cancerHigh riskMolecular response to treatmentImmune checkpoint inhibitionCycles of therapyInvasive bladder cancerEarly treatment intensificationRisk of progressionCycles of treatmentHigh gradeResponse to treatmentTime pointsMolecular responseHG recurrenceIntravenous atezolizumabPersistent CISBladder preservationEnsuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer
McConkey D, Baumann B, Greenberg S, DeGraff D, Delacroix S, Efstathiou J, Foster J, Groshen S, Kadel E, Khani F, Kim W, Lerner S, Levin T, Liao J, Milowsky M, Meeks J, Miyamoto D, Mouw K, Pietzak E, Solit D, Sundi D, Tawab-Amiri A, West P, Wobker S, Wyatt A, Apolo A, Black P. Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer. Bladder Cancer 2024, 10: 1-8. PMID: 38993535, PMCID: PMC11181871, DOI: 10.3233/blc-230082.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerClinical trialsBiomarker studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply